MDx/CDx Focus: CHMP Positive Opinion on Exelixis' Cometriq; Kalydeco in R117H-Mutated CF | GenomeWeb

Originally published Dec. 23.

EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

The European Committee for Medicinal Products for Human Use granted a positive opinion of the Exelixis' marketing authorization application for Cometriq (cabozantinib), which the firm is developing as a treatment for progressive, unresectable locally advanced, or metastatic medullary thyroid carcinoma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.